[Featured Stock] BlueMTech Hits Yearly High... Surge on Possibility of WigoBi Handling 'Secondary Distribution'

Wegovy Officially Released in Korea on the 15th
Blue M Tech Likely to Handle Second Distribution of Wegovy
'Explosive Popularity' from Wegovy's First Day in Korea

Blue M Tech recorded an all-time high during the year. This appears to be influenced by news that it is highly likely to handle the secondary distribution of the obesity treatment drug 'Wegovy' launched in Korea.

As of 9:43 a.m. on the 16th, Blue M Tech was trading at 27,950 KRW, up 3.52% (950 KRW) from the previous close. It reached a peak of 29,450 KRW early in the session. Blue M Tech, which was listed in December last year, recorded a peak price of 75,900 KRW and saw its price fall below 10,000 KRW earlier this year. However, since hitting a low point in August, it has continued its upward trend and is currently trading at its highest price this year.

Blue M Tech is the number one online pharmaceutical distribution company in Korea. It is known that the company is highly likely to take charge of the secondary distribution of the obesity treatment drug 'Wegovy,' which was officially launched in Korea the day before. Wegovy is showing signs of overheating as soon as it landed in Korea. On the first day of its launch, hospitals and clinics rushed to secure initial supplies, and online communities are sharing real-time information about 'holy places' where Wegovy can be purchased. Additionally, the order reception server of the online intermediary distributor, Jullic Pharma Korea, went down just an hour and a half after opening.